Big pharma players are embracing AI for decision-making, using apps that serve up real-time insights on project costs, success probabilities, supply chain constraints, and more.
But this shift isn’t without its challenges. Employees are grappling with the transition to a data-first strategy, and there are concerns about AI’s current ability to forecast breakthroughs and assess the implications of policies like the Inflation Reduction Act. There’s also a pressing need for a new breed of professionals skilled in both science and data science.
AI-powered portfolio decisions by Melanie Senior investigates this digital transformation in more detail, exploring its potential and its challenges.
